Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6677309
Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods
expired -
US 6673346
Compositions and methods for the treatment of sepsis
expired -
US 6673768
Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating)
expired -
US 6673602
Herpes simplex virus amplicon vector targeting system and method of using same
expired -
US 6673332
Assays for inhibitors of neuronal transport of Alzheimer's amyloid precursor protein
expired -
US 6673903
Mammalian cell cycle protein
expired -
US 6673778
Enzyme inhibitors for metabolic redirection
expired -
US 6673591
Methods for enhancing the production of viral vaccines in cell culture
expired -
US 6670451
Netrins
expired -
US 6667034
METHODS FOR REGULATING THE SPECIFIC LINEAGES OF CELLS PRODUCED IN A HUMAN HEMATOPOIETIC CELL CULTURE, METHODS FOR ASSAYING THE EFFECT OF SUBSTANCES ON LINEAGE-SPECIFIC CELL PRODUCTION, AND CELL COMPOSITIONS PRODUCED BY THESE CULTURES
expired -
US 6667036
Methods of treatment using antibodies to P-selectin glycoprotein ligand
expired -
US 6667041
Use of neurotoxin therapy for treatment of urologic and related disorders
expired -
US 6663857
In vivo gene transfer using implanted retroviral producer cells
expired -
US 6663886
Inhibition of cell-cell binding by lipid assemblies
expired -
US 6664230
Orally administered peptides to ameliorate atherosclerosis
expired -
US 6664040
Compositions and methods for delivery of a molecule into a cell
expired -
US 6663858
In Vivo gene transfer using implanted retroviral producer cells
expired -
US 6660767
Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
expired -
US 6660846
Vesicular amino acid transporter composition and method
expired -
US 6660530
Methods for labeling &bgr;-amyloid plaques and neurofibrillary tangles
expired -
US 6660484
Colorimetric glycopolythiophene biosensors
expired -
US 6657104
Transgenic mouse model for cardiac hypertrophy and methods of use thereof
expired -
US 6656963
Indole-3-carbinol (I3C) derivatives and methods
expired -
US 6656746
Antibodies to human kunitz-type inhibitor
expired -
US 6656465
Antibodies that mimic actions of neurotrophins
expired -
US 6656471
HIV-specific T-cell induction
expired -
US 6653452
Human IRAK-2
expired -
US 6653291
Composition and method for production of transformed cells
expired -
US 6653131
Method of treating systemic inflammatory response syndrome
expired -
US 6653351
Adjuvant chemotherapy for anaplastic gliomas
expired -
US 6653100
hKCa3/KCNN3 small conductance calcium activated potassium channel: A diagnostic marker and therapeutic target
expired -
US 6652833
Functionalized active-nucleus complex sensor
expired -
US 6649593
Modulators of SREBP processing
expired -
US 6649594
Compositions for metabolic protection and repair of lips
expired -
US 6649364
Anti-apoptotic compositions and methods using same
expired -
US 6649654
Methods for identifying and using IKK inhibitors
expired -
US 6649631
Compositions and methods for treating bone deficit conditions
expired -
US 6645463
Blood-pool selective carrier for lipophilic imaging agents
expired -
US 6645465
Annexin proteins and autoantibodies as serum markers for cancer
expired -
US 6642363
Polymers containing polysaccharides such as alginates or modified alginates
expired -
US 6638543
Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
expired -
US 6639105
Illudin analogs useful as antitumor agents
expired -
US 6638912
Peptide compositions mimicking TGF-&bgr; activity
expired -
US 6635676
Non-toxic antimicrobial compositions and methods of use
expired -
US 6632441
Mutants of streptococcal toxin a and methods of use
expired -
US 6632626
Methods of assaying farnesyl transferase
expired -
US 6632628
Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
expired -
US 6632434
Leptospiral major outer membrane protein, LipL 32
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory